
usd may pm et
summari compani primarili provid medic technolog product nich busi
price-to-earnings oper ep
base busi princip serv
stabl global health care sector histori
gener solid revenu profit growth howev
compani financi leverag remain higher
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
incorpor lower
target price base
multipl ep estim
ep vs
short estim lower ep
ep
sale increas
million expect
saw elev demand emea anesthesia
respiratori vascular access product
use address
patient heighten demand
product enough off-set weak
busi like mani peer
remov guidanc approxim
third portfolio expos elect
procedur volum anticip
declin precipit compar peer
seem less intent cut cost
confid indic urolift
procedur return rapidli sinc
procedur perform outpati
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview teleflex incorpor engag develop manufactur suppli
single-us medic devic use hospit health care provid common diagnost
therapeut procedur critic care surgic applic sell product hospit
healthcar provid global combin direct sale forc distributor
product use numer market varieti procedur depend upon one
end market procedur seven report segment vascular north america
emea asia oem segment
tfx vascular north america segment offer product facilit varieti critic care therapi
applic product primarili consist tfx arrow brand cathet relat
devic cathet posit system intervent north america segment consist
product use intervent cardiologist intervent radiologist vascular surgeon vein
practic north america anesthesia north america segment compris compani north
american pain manag airway manag product product like tfx airway
manufactur develop sell comprehens rang surgic product use varieti
europ middl east africa emea asia segment design manufactur distribut medic
devic primarili use critic care surgic applic cardiac care gener serv hospit
health care provid home health specifi region oem segment design manufactur
suppli devic instrument medic devic manufactur tfx busi
includ immateri oper segment respiratory/urolog north america intervent urolog
north america latin america
industri dynam medic devic industri highli competit compet mani
compani rang small start-up enterpris compani larger establish
market character new product develop technolog chang requir compani
continu develop acquir new product technolog remain competit compet
primarili basi clinic superior innov featur enhanc patient benefit product
reliabl perform custom sale support cost effect major end market
hospitals/health care provid revenu medic devic manufactur home
health tfx major competitor includ plc becton dickinson compani boston
vascular solut inc vascular solut neotract medic devic compani
develop commerci urolift system minim invas medic devic treat lower
urinari tract symptom due benign prostat hyperplasia bph vascular solut medic
devic compani develop market clinic product use minim invas coronari
financi trend tfx revenu grew billion bolster recent acquisit
adjust ep compani grew year-over-year reflect five-year compound
annual growth rate compound-annual-growth-rate septemb compani low moder level
debt net debt capit leverag ratio net debt trailing-twelve-month ebitda
free cash flow million million
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra keep hold opinion share teleflex incorpor
lift target base above-p
multipl ep estim warrant
premium due recent acquir higher growth busi ep
vs beat consensu expect lift ep
ep sale increas
constant currenc cc million driven solid cc growth
america million cc growth asia impress
currenc neg impact intervent urolog busi
remain strong sale grew cc million continu uptak
urolift devic manag note commerci team train
urologist total us intend roll-out urolift
aim fulli convert physician base second-gener
devic /kevin huang cfa
pm et cfra reiter hold opinion share teleflex incorpor
maintain target above-p
ep estim warrant premium due
recent acquir higher growth busi ep vs
equal estim lower ep initi
ep sale increas constant currenc
cc million driven cc growth
intervent north america segment million growth
oem segment million intervent urolog sale includ
tfx urolift devic million total sale
continu see urolift key driver sale growth especi
recent posit data devic urolift shonin approv japan
also obtain pre-market approv pma fda manta devic
global market manta approxim million
expect slow limit launch /kevin huang cfa
pm et cfra maintain hold opinion share teleflex incorpor
lower target price base multipl
ep estim ep vs
short estim lower ep
ep sale increas million
expect saw elev demand emea anesthesia
respiratori vascular access product use
address patient heighten demand product
enough off-set weak busi like mani peer
remov guidanc approxim third portfolio expos
elect procedur volum anticip declin precipit
compar peer seem less intent cut cost like
reflect manag busi confid indic urolift
procedur return rapidli sinc procedur perform
pm et cfra keep hold opinion share teleflex incorpor
lift target base multipl
ep estim ep vs
surpass estim lower ep
initi ep constant currenc basi sale
increas million led growth america
oem asia declin emea weak emea
partial due time phase certain distributor order
inventori level remain elev rel histor level
expect declin compani finish transit facil
implement process improv receiv day dso also elev
day vs day due implement
european medic devic regul tfx ep guidanc
project neg impact ep greater headwind
expect /kevin huang cfa
et cfra maintain hold opinion share teleflex incorpor
lift target base forward price-to-earnings
multipl ep estim ep
vs surpass estim recent oper margin
expans despit beat maintain ep estim
neg impact closur third-parti steril facil
constant currenc cc million led
america region revenu grew cc follow cc
growth emea asia oem sale inventori
day dsi increas day yoy day rais concern may
hold much inventori could pressur futur margin
manag note earn call increas tactic
move design enhanc custom servic increas safeti stock level
pm et cfra keep hold opinion share teleflex incorpor
rais target base forward price-to-earnings
multipl ep estim lift
multipl high end rang due increas confid
commerci execut ep vs fell short
estim lift ep sale
increas constant currenc cc million
expect driven impress cc growth america
million cc growth asia million strength asia
led sale growth china howev currenc continu strong
headwind asia neg impact sale slightli less
neg impact intervent urolog busi led
urolift product gener million sale reflect
cc yoy increas growth emea cc expect due
time certain order /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
